Free consultation Benefits Triple mechanism of action only GLP-1 + GIP + glucagon agonist 40 mg in pen 4 full doses of 10 mg (up to 16 weeks with gradual escalation) 12 needles included + ALLUVI dosing instructions Isotonic solution, pH 6.57.5 comfortable injection Up to 24% weight loss over 48 weeks (Phase 2 study, NEJM 2023) Cold chain delivery with cooling elements (28C) across Ukraine Free 24/7 DOZA specialist support throughout the entire course Retatrutide 40 mg (ALLUVI) detailed description Retatrutide by ALLUVI Healthcare the world's first triple agonist targeting GLP-1, GIP and glucagon receptors in a convenient injection pen
Clinical Studies on GLP-1 Agonists in Breast Cancer Patients Three recent analyses summarized in abstracts have reviewed the use of GLP-1 RAs for weight management in BC patients, with varying results
Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumptionII
Strong-smelling foods like fish, garlic, and onions cause problems for many users
By utilizing consistent warmth and 630nm Red LED therapy, it serves as a modern alternative to traditional hot compresses that often cool too quickly to be effective
Understanding GLP-1 Weight Loss Medication Options How Do Oral GLP-1 Tablets Compare to Injections
